Predicting the Unpredictable: Drug-Induced QT Prolongation and Torsades de Pointes

Peter J Schwartz, Raymond L. Woosley

Research output: Contribution to journalArticle

Abstract

Drug-induced long QT syndrome (diLQTS) and congenital LQTS (cLQTS) share many features, and both syndromes can result in life-threatening torsades de pointes (TdP). Our understanding of their mechanistic and genetic similarities has led to their improved clinical management. However, our inability to prevent diLQTS has resulted in removal of many medicines from the market and from development. Genetic and clinical risk factors for diLQTS and TdP are well known and raise the possibility of TdP prevention. Clinical decision support systems (CDSS) can scan the patient's electronic health records for clinical risk factors predictive of diLQTS and warn when a drug that can cause TdP is prescribed. CDSS have reduced prescriptions of QT-prolonging drugs, but these relatively small changes lack the power to reduce TdP. The growing genetic evidence linking diLQTS to cLQTS suggests that prevention of TdP in the future may require inclusion of both genetic and clinical predictors into CDSS.

Original languageEnglish
Pages (from-to)1639-50
Number of pages12
JournalJournal of the American College of Cardiology
Volume67
Issue number13
DOIs
Publication statusPublished - Apr 5 2016

Fingerprint

Torsades de Pointes
Long QT Syndrome
Clinical Decision Support Systems
Pharmaceutical Preparations
Electronic Health Records
Prescriptions

Keywords

  • Journal Article
  • Review

Cite this

Predicting the Unpredictable : Drug-Induced QT Prolongation and Torsades de Pointes. / Schwartz, Peter J; Woosley, Raymond L.

In: Journal of the American College of Cardiology, Vol. 67, No. 13, 05.04.2016, p. 1639-50.

Research output: Contribution to journalArticle

@article{f616ea56fbc0413887b4d0354f18291f,
title = "Predicting the Unpredictable: Drug-Induced QT Prolongation and Torsades de Pointes",
abstract = "Drug-induced long QT syndrome (diLQTS) and congenital LQTS (cLQTS) share many features, and both syndromes can result in life-threatening torsades de pointes (TdP). Our understanding of their mechanistic and genetic similarities has led to their improved clinical management. However, our inability to prevent diLQTS has resulted in removal of many medicines from the market and from development. Genetic and clinical risk factors for diLQTS and TdP are well known and raise the possibility of TdP prevention. Clinical decision support systems (CDSS) can scan the patient's electronic health records for clinical risk factors predictive of diLQTS and warn when a drug that can cause TdP is prescribed. CDSS have reduced prescriptions of QT-prolonging drugs, but these relatively small changes lack the power to reduce TdP. The growing genetic evidence linking diLQTS to cLQTS suggests that prevention of TdP in the future may require inclusion of both genetic and clinical predictors into CDSS.",
keywords = "Journal Article, Review",
author = "Schwartz, {Peter J} and Woosley, {Raymond L.}",
note = "Copyright {\circledC} 2016 American College of Cardiology Foundation. Published by Elsevier Inc. All rights reserved.",
year = "2016",
month = "4",
day = "5",
doi = "10.1016/j.jacc.2015.12.063",
language = "English",
volume = "67",
pages = "1639--50",
journal = "Journal of the American College of Cardiology",
issn = "0735-1097",
publisher = "Elsevier USA",
number = "13",

}

TY - JOUR

T1 - Predicting the Unpredictable

T2 - Drug-Induced QT Prolongation and Torsades de Pointes

AU - Schwartz, Peter J

AU - Woosley, Raymond L.

N1 - Copyright © 2016 American College of Cardiology Foundation. Published by Elsevier Inc. All rights reserved.

PY - 2016/4/5

Y1 - 2016/4/5

N2 - Drug-induced long QT syndrome (diLQTS) and congenital LQTS (cLQTS) share many features, and both syndromes can result in life-threatening torsades de pointes (TdP). Our understanding of their mechanistic and genetic similarities has led to their improved clinical management. However, our inability to prevent diLQTS has resulted in removal of many medicines from the market and from development. Genetic and clinical risk factors for diLQTS and TdP are well known and raise the possibility of TdP prevention. Clinical decision support systems (CDSS) can scan the patient's electronic health records for clinical risk factors predictive of diLQTS and warn when a drug that can cause TdP is prescribed. CDSS have reduced prescriptions of QT-prolonging drugs, but these relatively small changes lack the power to reduce TdP. The growing genetic evidence linking diLQTS to cLQTS suggests that prevention of TdP in the future may require inclusion of both genetic and clinical predictors into CDSS.

AB - Drug-induced long QT syndrome (diLQTS) and congenital LQTS (cLQTS) share many features, and both syndromes can result in life-threatening torsades de pointes (TdP). Our understanding of their mechanistic and genetic similarities has led to their improved clinical management. However, our inability to prevent diLQTS has resulted in removal of many medicines from the market and from development. Genetic and clinical risk factors for diLQTS and TdP are well known and raise the possibility of TdP prevention. Clinical decision support systems (CDSS) can scan the patient's electronic health records for clinical risk factors predictive of diLQTS and warn when a drug that can cause TdP is prescribed. CDSS have reduced prescriptions of QT-prolonging drugs, but these relatively small changes lack the power to reduce TdP. The growing genetic evidence linking diLQTS to cLQTS suggests that prevention of TdP in the future may require inclusion of both genetic and clinical predictors into CDSS.

KW - Journal Article

KW - Review

U2 - 10.1016/j.jacc.2015.12.063

DO - 10.1016/j.jacc.2015.12.063

M3 - Article

C2 - 27150690

VL - 67

SP - 1639

EP - 1650

JO - Journal of the American College of Cardiology

JF - Journal of the American College of Cardiology

SN - 0735-1097

IS - 13

ER -